- Home
- CHY vs JANX Comparison
CHY vs JANX Comparison
Compare CHY & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | JANX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.9M | 790.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHY | JANX |
|---|---|---|
| Price | $12.18 | $16.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $50.09 |
| AVG Volume (30 Days) | 226.5K | ★ 932.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.70 | $12.12 |
| 52 Week High | $12.14 | $35.34 |
Technical Indicators
Market Signals| Indicator | CHY | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 66.54 | 69.21 |
| Support Level | $11.19 | $12.93 |
| Resistance Level | N/A | $25.07 |
| Average True Range (ATR) | 0.21 | 0.66 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 100.00 | 80.37 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.